Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Haemophilus b conjugate vaccine (tetanus toxoid conjugate) + ViscoGel
- Development stage
- Preclinical
- Lead developer
- Sanofi
- Modality
- Vaccines & Immunotherapeutics, Hydrogel Systems → Drug Delivery Systems
- Administration
- Intramuscular
01
Overview
Haemophilus b conjugate vaccine (ActHIB) is a lyophilized, purified capsular polysaccharide of Haemophilus influenzae type b covalently bound to tetanus protein, indicated for the prevention of invasive disease caused by H. influenzae type b in children 2 months through 5 years of age. It works by inducing an immune response that generates antibodies against the bacterial polysaccharide capsule, thereby preventing infection[1][2][5][6]. ViscoGel is an innovative chitosan-based hydrogel adjuvant developed to enhance the immunogenicity and efficacy of vaccines. When used as an adjuvant with ActHIB, ViscoGel aims to improve immune responses and potentially allow for dose sparing or improved protection[3][4]. The combination has been evaluated preclinically and clinically for safety and efficacy as a prophylactic vaccination strategy against Hib disease[3][4]. Sanofi Pasteur is the developer and manufacturer of ActHIB; ViscoGel was developed within European research consortia focused on novel adjuvants.
- Other names
- Haemophilus influenzae type b conjugate vaccine (tetanus protein–conjugate)Hib vaccine (ActHIB)Haemophilus b conjugate vaccine (tetanus toxoid conjugate)
02
Targets
TT (Tetanus toxoid)
Beyond the preview
Go deeper on Haemophilus b conjugate vaccine (tetanus toxoid conjugate) + ViscoGel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Haemophilus b conjugate vaccine (tetanus toxoid conjugate) + ViscoGel.